Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three antibiotics—amoxycillin, clavulanic acid, and ciprofloxacin. Amoxycillin is a penicillin-type beta-lactam antibiotic that inhibits bacterial cell wall synthesis, leading to cell death. Clavulanic acid is a beta-lactamase inhibitor that protects amoxycillin from degradation by beta-lactamase enzymes produced by resistant bacteria, thereby extending its spectrum of activity[3][6]. Ciprofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication and transcription in bacteria[10]. This triple combination would provide broad-spectrum antibacterial coverage against both gram-positive and gram-negative organisms—including many resistant strains—and may be considered in severe or mixed infections where multidrug-resistant pathogens are suspected. However, such combinations are not standard therapy and should only be used under strict medical supervision due to the risk of increased side effects and drug interactions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amoxycillin + clavulanic acid + ciprofloxacin.